Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Respinova Ltd.

Pressure-pulsation home-use device for managing COPD

This article was originally published in Start Up

Executive Summary

Respinova Ltd. has developed a noninvasive home-use device to help patients manage COPD’s debilitating symptoms. The PulseHaler is similar to continuous positive airway pressure devices used for sleep apnea, but it is designed to treat the very small terminal airways that are blocked as a result of COPD.

You may also be interested in...



Bellwether Wuxi Biologics' Plunge Indicative Of China Biotech Challenges

Major Chinese biopharma contract services group WuXi Biologics' share price plummeted after it said external factors would contribute to it missing original revenue targets this year in multiple areas.

Cosmetic And Personal Care Weekly Trademarks Review: 5 December

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

As Biopharma Seeks Broader IRA Orphan Exclusion, Study Urges Boosting Savings By Eliminating It

Research takes deep dive into the implications around exempting certain orphan drugs that may qualify for the Inflation Reduction Act’s Medicare price negotiation program, including the effect of the exemption on Medicare spending and the revenue potential of those drugs.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037891

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel